312 related articles for article (PubMed ID: 23983262)
1. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo.
Oueslati A; Schneider BL; Aebischer P; Lashuel HA
Proc Natl Acad Sci U S A; 2013 Oct; 110(41):E3945-54. PubMed ID: 23983262
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation.
Dahmene M; Bérard M; Oueslati A
J Biol Chem; 2017 Mar; 292(9):3919-3928. PubMed ID: 28154193
[TBL] [Abstract][Full Text] [Related]
3. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.
Inglis KJ; Chereau D; Brigham EF; Chiou SS; Schöbel S; Frigon NL; Yu M; Caccavello RJ; Nelson S; Motter R; Wright S; Chian D; Santiago P; Soriano F; Ramos C; Powell K; Goldstein JM; Babcock M; Yednock T; Bard F; Basi GS; Sham H; Chilcote TJ; McConlogue L; Griswold-Prenner I; Anderson JP
J Biol Chem; 2009 Jan; 284(5):2598-2602. PubMed ID: 19004816
[TBL] [Abstract][Full Text] [Related]
7. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2.
Wang R; Wang Y; Qu L; Chen B; Jiang H; Song N; Xie J
Neurochem Int; 2019 May; 125():127-135. PubMed ID: 30797969
[TBL] [Abstract][Full Text] [Related]
8. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
[No Abstract] [Full Text] [Related]
9. Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies.
Weston LJ; Stackhouse TL; Spinelli KJ; Boutros SW; Rose EP; Osterberg VR; Luk KC; Raber J; Weissman TA; Unni VK
J Biol Chem; 2021; 296():100273. PubMed ID: 33428941
[TBL] [Abstract][Full Text] [Related]
10. Icariin Inhibits Overexpression and Aggregation of α-Synuclein in A53T α-Synuclein Transgenic Mice by Regulating Parkin and PLK2.
Ma D; Shen C; Zhang X; Zhang L; Li L
J Integr Neurosci; 2023 Nov; 22(6):166. PubMed ID: 38176950
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein.
Rodríguez-Nogales C; Garbayo E; Martínez-Valbuena I; Sebastián V; Luquin MR; Blanco-Prieto MJ
Int J Pharm; 2016 Nov; 514(1):142-149. PubMed ID: 27863657
[TBL] [Abstract][Full Text] [Related]
12. Silencing synuclein at the synapse with PLK2.
Looyenga BD; Brundin P
Proc Natl Acad Sci U S A; 2013 Oct; 110(41):16293-4. PubMed ID: 24072649
[No Abstract] [Full Text] [Related]
13. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.
Fitzgerald K; Bergeron M; Willits C; Bowers S; Aubele DL; Goldbach E; Tonn G; Ness D; Olaharski A
Toxicol Appl Pharmacol; 2013 May; 269(1):1-7. PubMed ID: 23466428
[TBL] [Abstract][Full Text] [Related]
15. miR-101-3p Contributes to
Zhang M; Liu W; Zhang Q; Hu H
J Healthc Eng; 2021; 2021():6147434. PubMed ID: 34234930
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2.
Wang S; Xu B; Liou LC; Ren Q; Huang S; Luo Y; Zhang Z; Witt SN
Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16119-24. PubMed ID: 22988096
[TBL] [Abstract][Full Text] [Related]
17. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
Buck K; Landeck N; Ulusoy A; Majbour NK; El-Agnaf OM; Kirik D
Neurobiol Dis; 2015 Jun; 78():100-14. PubMed ID: 25818009
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein.
Kofoed RH; Betzer C; Ferreira N; Jensen PH
Neurobiol Dis; 2020 Mar; 136():104720. PubMed ID: 31881263
[TBL] [Abstract][Full Text] [Related]
19. DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells.
Tan S; Zhao J; Wang P
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37387444
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
